Immuneering Corporation Class A Common Stock (IMRX)
Stock · NASDAQ · Health Care
$3.59as of 10/16/2026
Price chart
Active signals
IMRX Signal Track Record
How signals performed across all stocks →What IMRX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 42 | -6.7% | 38% | October 8, 2026 |
| Bollinger Band Breakout | 26 | -7.2% | 46% | August 12, 2026 |
| Bollinger Band Breakdown | 18 | -0.2% | 50% | October 6, 2026 |
| 200-Day Moving Average TouchActive now | 12 | -0.3% | 50% | August 19, 2026 |
| Any 20-session window (baseline) | -3.3% | 44% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About IMRX
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical tri…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 57
- Website
- immuneering.com/
Fundamentals
- 1-day range
- $3.59$3.86
- Market cap
- $288.55M
- P/E (trailing)
- —
- P/E (forward)
- -2.87
- EPS (trailing)
- $-1.03
- Dividend yield
- —
- Beta
- 0.33
- Avg. volume
- 703.6K
How Immuneering Corporation Class A Common Stock Makes Money
Where the revenue actually goes — FY2022 annual results
Source: 10-K filed Mar 6, 2023 · via SEC EDGAR / Finnhub
Forecasts
6 analyst ratings
Immuneering Corporation Class A Common Stock Competitors
Chosen by industry and closest market cap.
- IMRXImmuneering Corporation Class A Common Stock$3.59▼ 1.37%Market cap $288.55MP/E —$3.6$8.48
- FULCFulcrum Therapeutics Inc. Common Stock$3.65▼ 0.54%Market cap $287.64MP/E —$2.83$15.74
- TTRXTurn Therapeutics Inc. Common Stock$10.57▼ 8.80%Market cap $286.26MP/E —$2.57$26.5
- ALXOALX Oncology Holdings Inc. Common Stock$1.06▲ 6.00%Market cap $283.93MP/E —$0.8617$2.66
- CAMPCAMP4 Therapeutics Corporation Common Stock$3.17▼ 8.12%Market cap $282.25MP/E —$2.86$7.75
- BCYCBicycle Therapeutics plc American Depositary Shares$3.46▼ 3.89%Market cap $277.87MP/E —$3.33$9.08
- AMRNAmarin Corporation plc$11.32▼ 2.16%Market cap $301.21MP/E —$11.34$20.9
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| IMRX Immuneering Corporation Class A Common Stock | $288.55M | — | $3.59 | ▼ 1.37% | $3.6$8.48 |
| FULC Fulcrum Therapeutics Inc. Common Stock | $287.64M | — | $3.65 | ▼ 0.54% | $2.83$15.74 |
| TTRX Turn Therapeutics Inc. Common Stock | $286.26M | — | $10.57 | ▼ 8.80% | $2.57$26.5 |
| ALXO ALX Oncology Holdings Inc. Common Stock | $283.93M | — | $1.06 | ▲ 6.00% | $0.8617$2.66 |
| CAMP CAMP4 Therapeutics Corporation Common Stock | $282.25M | — | $3.17 | ▼ 8.12% | $2.86$7.75 |
| BCYC Bicycle Therapeutics plc American Depositary Shares | $277.87M | — | $3.46 | ▼ 3.89% | $3.33$9.08 |
| AMRN Amarin Corporation plc | $301.21M | — | $11.32 | ▼ 2.16% | $11.34$20.9 |
P/E shows — for peers not currently carrying a live signal of their own.
Insider Activity
Insider Actions →- Andrew Gengos · July 16, 2026 · Grant650.0K
- Benjamin J. Zeskind · June 23, 2026 · Buy2.4K @ $4.56
- Brett Matthew Hall · June 15, 2026 · Buy6.0K @ $4.15
- Peter Feinberg · June 11, 2026 · Grant33.4K
- KEATING LAURIE · June 11, 2026 · Grant33.4K
- Diana Hausman · June 11, 2026 · Grant33.4K
- Thomas J. Schall · June 11, 2026 · Grant33.4K
- CARPENTER ROBERT J · June 11, 2026 · Grant33.4K
Institutional Ownership
March 31, 2026
- Total shares held
- 27.22M
- Total value held
- $133.03M
- Institutional holders
- 92
- Unknown9.70M
- Unknown2.71M
- Unknown2.00M
- Unknown1.83M
- Unknown1.51M
- Unknown1.10M
- Unknown637.9K
- Unknown545.1K
- Unknown529.1K
- Unknown400.4K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Immuneering to Present Data at ESMO Congress 2026
Immuneering announced it will present data at the upcoming ESMO Congress in 2026. This event is relevant as it provides a future opportunity for the company to share clinical updates with the medical community. The stock is currently trading below its 52-week high, with analysts maintaining a wide range of price targets.
Immuneering to Present Data at ESMO Congress 2026. Immuneering announced it will present data at the upcoming ESMO Congress in 2026. This event is relevant as it provides a future opportunity for the company to share clinical updates with the medical community. The stock is currently trading below its 52-week high, with analysts maintaining a wide range of price targets.